Oct 14, 2024 Fight against medicine shortages: the French Medicines Agency (ANSM) imposes fines totalling €8 million By Caroline Arrighi-Savoie Johanna Harelimana Nahla Ghouali On 24 September, the French National Agency for the Safety of Medicines and Health Products (ANSM) announced fines totalling €8 million...
Oct 09, 2024 Case C-237/22 of the CJEU – Clarification of the concepts of “Significant Benefit” and “Clinical Superiority” By Marc Martens Benedicte Mourisse The CJEU brings clarity, on the concepts of “Significant Benefit” and “Clinical Superiority” with respect to Orphan Medicinal Products...
Sep 17, 2024 The DNA of Life Sciences Deals By James Baillieu Maria John The life sciences sector, comprising of sub-sectors like pharmaceuticals, medical devices, diagnostics and services, aims to cure disease...
Aug 08, 2024 New EU Pharmaceutical Reform: Key Changes and Impacts on Orphan Medicinal Products By Anna Koster Hester Borgers Introduction to the EU Pharmaceutical Reform After the European Commission published the proposed regulation regarding the EU...
Jul 30, 2024 New UK government’s plans for life sciences: the people and policies explained By Sally Shorthose Heidi Hurdle Charlotte Getz The UK life sciences industry takes centre-stage in two of the new Labour government’s “Five Missions For National Renewal”: economic...